NSCLC

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

NSCLC
Nov 20, 2024, 19:12 | Blog
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC
IASLC (The International Association for the Study of Lung Cancer) shared a post on X:…
Nov 20, 2024, 16:38 | Insight
Herbert Loong: NTRK gene fusion testing in the management of NSCLC
Herbert Loong, Chair-Elect of the International Affairs Committee of ASCO, shared a post on X…
Nov 20, 2024, 15:19 | Insight
Eric Lim: Immunotherapy - before, after or both?
Eric Lim, Professor of Thoracic Surgery at Royal Brompton Hospital, shared his recent article on…
Nov 20, 2024, 11:30 | Insight
Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment
Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…
Nov 19, 2024, 13:43 | Insight
Highlights from New York Lung Cancers Symposium 2024 by Stephen V Liu
The New York Lung Cancers Symposium 24 (NYLung24) took place on 16th of November 2024,…
Nov 19, 2024, 10:18 | Insight
Anita McGrath’s Advocacy Journey in Lung Cancer - IASLC
IASLC shared a post on X: "Anita McGrath’s Advocacy Journey in Lung Cancer.   Anita McGrath,…
Nov 17, 2024, 07:43 | Blog
Tanja Obradovic: Important milestone for Dizal Pharmaceutical with sunvozertinib NDA submission
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Nov 16, 2024, 06:55 | Blog
Jill Feldman: Updated living guidelines for treating stage IV NSCLC with driver alterations
Jill Feldman, Co-Founder EGFR Resisters and a member of the programmatic panel for the Department…
Nov 14, 2024, 13:11 | Blog
American Society of Clinical Oncology's new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Check out our new…
Nov 14, 2024, 12:14 | Blog
Targeted therapy advancements in NSCLC - ACS Journal Cancer
ACS Journal Cancer posted the following on X: “Targeted therapy plays an important role for…
Nov 13, 2024, 23:35 | Insight
Raffaele Colombo: New BLA submitted for patients with EGFR-m NSCLC
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article on X: “Dato-DXd…
Nov 13, 2024, 16:08 | Blog
Evolving role of Radiation in early stage NSCLC by Dr. Annalisa Nardone
Stephen V Liu, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown…
Nov 12, 2024, 19:34 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Nov 12, 2024, 14:55 | Blog
Lissandra Dal Lago: Discussing Innovative endpoints for the development of new treatment strategies in Geriatric Oncology
Lissandra Dal Lago, Chair EORTC Older Adult Council at European Organisation for Research and Treatment of…
Nov 11, 2024, 17:12 | Blog
Stephen Liu: The Importance of Waiting for Biomarker Results in NSCLC
Stephen Liu, Associate Professor of Medicine at Georgetown University, shared a post on X: "It…
Nov 11, 2024, 04:17 | Insight
Advantage of SBRT over Surgery for early-stage NSCLC, study by Jochem Kaas
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at…
Nov 9, 2024, 18:21 | Blog
Aakash Desai Discusses Key Findings on ADCs in NSCLC Treatment
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted the following on LinkedIn: “In…
Nov 9, 2024, 18:17 | Blog
Katsuaki Maehara: Using targeted NGS analysis for EGFR classical mutations in NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “EGFR classical mutated NSCLC Frequency…
Nov 9, 2024, 11:23 | Blog
European Organisation for Research and Treatment of Cancer webinar on innovative study designs for older adults
EORTC - European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:…
Nov 8, 2024, 20:09 | Insight
Narjust Florez: Sarah Waliany on mechanisms of resistance to first-line vs. later-line Alectinib for ALK and NSCLC
Narjust Florez, Thoracic Medical Oncologist at the Dana-Farber Brigham Cancer Center, shared a post on…
Nov 8, 2024, 19:08 | Blog
Shahrin Ahmed: Looking back at the progress made in cell and gene therapy during LCAM 2024
Shahrin Ahmed, Medical specialist in oncology at the Canadian Cancer Society, shared a post on…
Nov 8, 2024, 13:58 | Blog
Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials
Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent…
Nov 3, 2024, 16:27 | Insight
Alessandro Di Federico: EFS in patients with resectable NSCLC treated with neoadjuvant Chemo-IO
Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a…
Nov 3, 2024, 13:55 | Insight
Highlights from JLCS24 by Stephen Liu
The 65th Annual Meeting of the Japanese Lung Cancer Society was held at PACIFICO Yokohama…
Nov 2, 2024, 05:07 | Blog
Razelle Kurzrock: Expanding HER2 horizons - Implications for NSCLC and beyond
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center,…
Nov 1, 2024, 17:46 | Blog
Hidehito Horinouchi: Early Stage NSCLC at ACLC24 session
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:…
Oct 31, 2024, 09:03 | Insight
Jarushka Naidoo: Maintenance Pembrolizumab with or without Olaparib for Advanced Squamous NSCLC
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin, shared a post on X about…
Oct 29, 2024, 22:00 | Blog
Jill Feldman: Hope and reality are NOT mutually exclusive
Jill Feldman, Co-Founder EGFR Resisters, shared a post by Katsuaki Maehara, Director of Medical Education…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 29, 2024, 10:11 | Insight
Stephen V Liu: Real-world 5-year survival with first line pembrolizumab in PD-L1 high NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Oct 28, 2024, 14:45 | Blog
Stephen V Liu: Immunotherapy for NSCLC discussed at the Emirates Oncology Society meeting
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Oct 26, 2024, 11:11 | Insight
Giuseppe Banna: Key considerations for implementing the LAURA study findings into clinical practice
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on…
Oct 25, 2024, 16:19 | Insight
EGFR-mutated oligo-organ metastatic NSCLC, summarised by Katsuaki Maehara
Katsuaki Maehara ,Director of Medical Education Colleagues, shared a post on X: " EGFR-mutated oligo-organ…
Oct 25, 2024, 13:51 | Blog
Drew Moghanaki: Standard of care for stage III NSCLC remains immunotherapy after CRT
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA,…
Oct 24, 2024, 13:05 | Blog
Concurrent thoracic radiotherapy improves the PFS and OS with acceptable toxicity in EGFR-mutated NSCLC
Gustavo Viani shared a post on Linkedin: ''Concurrent thoracic radiotherapy improves the PFS and OS…
Oct 23, 2024, 18:22 | Insight
Stephen Liu: What role does surgery play for patients with stage IV NSCLC?
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a post…
Oct 22, 2024, 15:54 | Blog
Chul Kim: Jennifer A. Marks on KRAS mutant NSCLC at DC Lung 24
Chul Kim, Associate Professor at Georgetown University, shared a post on X: "Great talk by…
Oct 21, 2024, 08:47 | Blog
Nagla Abdel Karim: Advances in molecular targets for NSCLC
Nagla Abdel Karim shared the following on X: “Mariam Alexander presents all about before &…
Oct 20, 2024, 19:15 | Insight
Gustavo Viani: Osimertinib post-CRT as the standard of care in unresectable stage III EGFR mutated NSCLC
Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital…
Oct 20, 2024, 17:47 | Drugs
Stephen V Liu: Long-term survival with nivolumab and ipilimumab in advanced NSCLC
Stephen V Liu shared on X: "Long-term survival (median f/u 73.7m) with nivolumab and ipilimumab…
Oct 20, 2024, 14:46 | Blog
Chul Kim: Neoadjuvant and perioperative chemoimmunotherapy in resectable NSCLC
Chul Kim shared on X: “Neoadjuvant and periop chemoimmunotherapy regimens have improved outcomes in resectable…
Oct 20, 2024, 11:34 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Oct 19, 2024, 15:57 | Insight
FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial
The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…
Oct 18, 2024, 13:52 | Insight
Hidehito Horinouchi: Oral Abstract Session 1 at ACLC24
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:…
Oct 18, 2024, 12:56 | Blog
Jonathan Spicer: Proud of our team’s results in minimally invasive lung resection
Jonathan Spicer, Medical Director of the McGill Thoracic Oncology Program, shared a post on X:…
Oct 17, 2024, 16:04 | Insight
Estela Rodriguez: Novocure’s Optune Lua TTF (device) plus docetaxel or Immunotherapy for 2L NSCLC
Estela Rodriguez shared a post on X: "Its only Tuesday and we have another ⁦FDA…
Oct 17, 2024, 15:52 | Blog
Oncology Brothers: Last 4 weeks in Lung Cancer
Oncology Brothers shared a post on X: "Last 4 weeks in Lung Cancer: 1. PR:…
Oct 16, 2024, 17:00 | Insight
Biagio Ricciuti: 5-year update from the NADIM trial
Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et…
Oct 16, 2024, 13:23 | Blog
Tackling global health inequities in lung cancer - EGFR Positive Lung Cancer UK
EGFR Positive Lung Cancer UK posted the following on X: “Lung cancer is challenging enough…
Oct 16, 2024, 12:05 | Insight
Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer
Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had…
Oct 15, 2024, 17:29 | Blog
Jill Feldman: Interesting finding for people with EFGR lung cancer that transforms to SCLC
Jill Feldman shared a post on X by Stephen V Liu adding: "Very interesting finding…
Oct 14, 2024, 13:56 | Insight
Katsuaki Maehara: Comprehensive Genome Profiling using NGS
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: “Comprehensive Genome Profiling…
Oct 14, 2024, 13:40 | Insight
Retrospective report on EGFR mutant NSCLC transformed to SCLC, suggested by Stephen V Liu
Stephen V Liu shared a post on X: "Retrospective report in European Journal of Cancer on…
Oct 12, 2024, 17:30 | Blog
Stephen V Liu: Should patients with stage III ALK NSCLC receive adjuvant alectinib alectinib?
Stephen V Liu shared a post on X: "POLL: For patients with resected stage III…
Oct 11, 2024, 19:32 | Insight
Hung Trinh: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Hung Trinh shared a post on LinkedIn: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.…
Oct 11, 2024, 15:17 | Blog
Katsuaki Maehara: Summary of Major Clinical Trials of ICI's in Early Stage NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X: ''Summary of Major…
Oct 9, 2024, 16:38 | Blog
Stephen V Liu: Case report of MET mediating resistance to entrectinib in ROS1 NSCLC
Stephen V Liu shared a post on X: "Case report of MET mediating resistance to entrectinib…
Oct 9, 2024, 15:23 | Blog
Upal Basu Roy: How immune cells can be engineered to target EGFR+ NSCLC
Upal Basu Roy, Executive Director of Research at LUNGevity Foundation, shared about a Facebook Live…
Oct 9, 2024, 11:40 | Insight
Datopotamab Deruxtecan Trial Shows Negative OS in TROPION-Lung 01 - Panot Sainamthip
"Recent data updates from the International Association for the Study of Lung Cancer 2024 World…
Oct 8, 2024, 15:29 | Insight
Jarushka Naidoo: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab in NSCLC
Jarushka Naidoo shared a post on X: “Long-Term Outcomes 1L Ipilimumab/Nivolumab/-Chemo v Chemo in PDL1<1%…
Oct 8, 2024, 01:45 | Blog
Stephen V Liu: Jordi Remon discusses perioperative IO for NSCLC at ILCS24
Stephen V Liu shared a post on X: "Dr. Jordi Remon discusses perioperative IO for NSCLC…
Oct 7, 2024, 16:46 | Insight
Outcomes in patients with oligoprogression following 1st line IO or ChemoIO
Gerry Hanna, Radiation Oncologist at St James's Hospital, shared a post on X: "Very intresting…
Oct 7, 2024, 08:15 | Insight
Choosing between Stereotactic and Hypofractionated Radiotherapy for inoperable Stage I NSCLC, summarised by Gustavo Viani
Gustavo Viani, Associate Professor, Faculdade de Medicina de Ribeirão Preto (FMRP) da USP, shared a post…
Oct 6, 2024, 13:47 | Blog
Ana I. Velázquez Mañana: Lung Cancer management updates from 2024 by Weill Cornell Medicine Meyer Cancer Center
Ana I. Velázquez Mañana shared a post on X: ''Christine Garcia from Weill Cornell Medicine…
Oct 5, 2024, 23:43 | Insight
MD Anderson Research Highlights for the 2024 World Conference on Lung Cancer
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent…
Oct 5, 2024, 13:04 | Insight
Highlights from ILCS24 by Stephen V Liu
The 6th International Lung Cancer Summit took place as a hybrid event in Lausanne, Switzerland,…
Oct 5, 2024, 08:24 | Insight
Tanja Obradovic: New Treatment for NSCLC Patients Targeting cMet Over-Expression
Tanja Obradovic shared a post on LinkedIn: "Novel antibody-drug conjugate (ADC) may be coming for…
Oct 5, 2024, 02:12 | Insight
Eric K. Singhi: FDA Oncology approves amivantamab and chemo for EGFR and NSCLC
Eric K. Singhi shared a post on X: “FDA Oncology approves amivantamab and chemo for…
Oct 4, 2024, 16:47 | Blog
Jillian Tsai: Quad Shot can be used in NSCLC, HN, and other cancers
Jillian Tsai, Radiation Oncologist at Princess Margaret Cancer Centre, Toronto, shared a post by Gerry…
Oct 4, 2024, 15:32 | Insight
Gustavo Viani: Neoadjuvant immunotherapy for unresectable stage III NSCLC followed by CRT
Gustavo Viani shared a post on LinkedIn about a recent paper by Helen Ross et al. published…
Oct 4, 2024, 15:19 | Blog
Tanja Obradovic: FDA granted approval to selpercatinib for advanced or metastatic medullary thyroid cancer with a RET mutation
Tanja Obradovic shared a post on LinkedIn: "Outstanding news for patients with metastatic medulary thyroid…
Oct 4, 2024, 15:05 | Insight
Iván R. González: Meta - analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:…
Oct 4, 2024, 09:43 | Insight
Deridre Kelly: Ph2 Capmatinib in METex14 NSCLC
Deridre Kelly, Professor of Paediatric Hepatology at the University of Birmingham, sharen on X: "New…
Oct 4, 2024, 06:03 | Drugs
FDA approved Neoadjuvant/Adjuvant Nivolumab for resectable NSCLC
FDA Approval Introduces New Treatment Options for Adults with Resectable Lung Cancer Lacking Key Genetic…
Oct 3, 2024, 07:28 | Blog
Exploring HER2 targeting in Solid Tumours focusing on NSCLC - touch RESPIRATORY
touch RESPIRATORY shared a post on X: "HER2 targeting insights! Join leading experts Dr Razelle…
Oct 3, 2024, 07:22 | Blog
Tanja Obradovic: AbbVie submitted telisotuzumab vedotin in adult NSCLC patients with tumors with EGFR non squamous histology
Tanja Obradovic shared a post on LinkedIn: "Completely new treatment option by novel antibody-drug conjugate (ADC)…
Oct 2, 2024, 15:31 | Blog
Amol Akhade: How to define oligometastatic NSCLC
Amol Akhade shared a post on LinkedIn: ''Oligometastatic NSCLC. How to define it (Oligorecurrent, oligopersistant,…
Oct 2, 2024, 14:41 | Insight
Stephen Liu: Phase Ib study of naporafenib with rineterkib or trametinib in NSCLC
Stephen Liu shared a post on X about a recent paper by David Planchard et…
Oct 2, 2024, 08:24 | Blog
Tanja Obradovic: FDA just approved Osimertinib for adult patients with locally advanced, unresectable non-small cell lung cancer
Tanja Obradovic shared a post on LinkedIn: ''FDA just approved Osimertinib (Tagrisso), a third-generation EGFR-directed…
Oct 1, 2024, 14:30 | Blog
Sarah Louden: Cancer doesn’t just touch the person diagnosed
Sarah Louden posted on LinkedIn: "Gilead Oncology  Tears. Gratitude. Deep inspiration. My son Joseph has…
Oct 1, 2024, 10:23 | Blog
Stephen Liu: The optimal duration of immunotherapy for NSCLC at DCLung24
Stephen Liu shared a post on X: "Dr. Matthew Lee from Montefiore, ME Cancer Center,…
Oct 1, 2024, 05:09 | Blog
Lyndon Walsh: Shanique Ries discussing surgical resection of Stage IV NSCLC patients at ITSOS2024
Lyndon Walsh, Lung Cancer ResearcherLung at McGill University Health Centre, shared on X: "Thought provoking presentation…
Sep 30, 2024, 08:39 | Opinion
Tanja Obradovic: Strategy of clinical development in oncology requires global considerations
Tanja Obradovic shared the following on LinkedIn: “Strategy of clinical development in oncology always encompasses…
Sep 29, 2024, 15:21 | Blog
Joe Y Chang: Intensity-modulated proton vs photon therapy with concurrent chemo in medical inoperable stage III NSCLC
Joe Y Chang, Professor and Director, Stereotactic Ablative Radiotherapy Program, MD Anderson Cancer Center, shared…
Sep 29, 2024, 06:34 | Insight
Picks from Lung Cancer Cocktail With Science by Stephen V Liu
The Lung Cancer Cocktail With Science 2024 conference took place on September 27th in Milan,…
Sep 27, 2024, 15:31 | Dialogues
ASCO24 Updates: Dr. Yuichi Ozawa - Key Factors Affecting PFS in NSCLC Patients
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Sep 27, 2024, 15:04 | Blog
Joshua Bauml: The U.S. FDA approved our targeted therapy in combination with for NSCLC with specific EGFR mutations
Joshua Bauml, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, shared a post on…
Sep 26, 2024, 15:37 | Blog
Stephen V Liu: Retrospective report on treatment post osimertinib for EGFR NSCLC
Stephen V Liu shared a post on X, about recent paper published in Clinical Lung…
Sep 26, 2024, 15:35 | Blog
Jarushka Naidoo: TL01 Phase III Datopotamab-Deruxtecan vs Docetaxel in second-line NSCLC
Jarushka Naidoo shared a post on X, about recent paper published in Journal of Clinical…
Sep 26, 2024, 14:34 | Blog
Yakup Ergun: Survival and recurrence rates following SBRT or surgery in operable Stage I NSCLC
Yakup Ergun, Medical Oncologist at Antalya City Hospital, shared a post on X, about recent…
Sep 25, 2024, 14:39 | Blog
Stephen V Liu: Stephen R Broderick guides a discussion on early stage NSCLC at DCLung24
Stephen V Liu posted on X: "Stephen R Broderick guides a discussion on early stage…
Sep 24, 2024, 22:58 | Blog
Isabelle Schmitt-Opitz: Session on 'Promises and Pitfalls in Earlier Stage NSCLC' at ESMO24
Isabelle Schmitt-Opitz shared a post on LinkedIn: ''It was a pleasure to chair this highly…
Sep 24, 2024, 16:52 | Blog
Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…
Sep 24, 2024, 13:32 | Insight
Jarushka Naidoo: Stage III ALK+ NSCLC - consolidation ALK TKI vs Durvalumab vs Observation
Jarushka Naidoo shared on X: "Stage III ALK+ NSCLC: consolidation ALK Tyrosine Kinase Inhibitors versus…
Sep 24, 2024, 11:04 | Blog
Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC
Stephen V Liu shared a post on X: ''In this episode of the IASLC podcast…
Sep 23, 2024, 20:18 | Blog
Antonio Passaro: Honored to have presented the SOHO-02 clinical trial
Antonio Passaro shared a post on LinkedIn: "I am truly honored to have presented the…
Sep 23, 2024, 09:48 | Insight
Heidi Ko: Alarming Biomarker Testing Gaps in NSCLC
Heidi Ko, Medical Director, Medical Affairs, Labcorp Drug Development, posted the following on LinkedIn: “These…
Sep 22, 2024, 15:15 | Insight
Dexamethasone reduces IRRs in patients with EGFR-mutated NSCLC treated with intravenous RYBREVANT
Johnson and Johnson announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional…
Sep 22, 2024, 14:45 | Blog
Amol Akhade: ADC In NSCLC
Amol Akhade shared a post on LinkedIn: "ADC In NSCLC. All Drugs in One Slide .…
Sep 20, 2024, 13:27 | Blog
Stephen V Liu: FDA approved MARIPOSA2
Stephen V Liu shared on X: “FDA approved MARIPOSA2: amivantamab plus chemotherapy for EGFR NSCLC…
All: 470 Posts: 1 - 100
Special Coverage